3528 results for «2025-12-19至2026-01-05+智光电气+异动分析»

Filter By

3528 results

Mitral and aortic transcatheter valve-in-valve intervention - LIVE case

14 Feb 2026 – From PCR Tokyo Valves 2026

Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...

Mitral and aortic transcatheter valve-in-valve intervention - LIVE case

TEER in complex tricuspid regurgitation - LIVE case

14 Feb 2026 – From PCR Tokyo Valves 2026

A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.

Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.

LIVE Educational Case...

TEER in complex tricuspid regurgitation - LIVE case

Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification

27 Feb 2026 – From Euro4C Annual Meeting

Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.

Introducing next era of coronary intravascular lithotripsy: aero-volution in calcium modification

Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs

27 Feb 2026 – From Euro4C Annual Meeting

This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.

Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs

Prevention and management of TAVI complications

14 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...

Prevention and management of TAVI complications

Primary mitral TEER in small anatomy - LIVE case

15 Feb 2026 – From PCR Tokyo Valves 2026

An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).

One Pascal ACE device was implanted.

LIVE Educational Case from Nagoya...

Primary mitral TEER in small anatomy - LIVE case

Guidelines update

15 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

Guidelines update

Future devices and techniques for structural heart disease

15 Feb 2026 – From PCR Tokyo Valves 2026

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.

Future devices and techniques for structural heart disease

EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data

EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial

21 May 2025

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial

Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome

21 May 2025 – From EuroPCR 2025

In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...

Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after DCS insertion in ACS

Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study

21 May 2025 – From EuroPCR 2025

Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.

They review the trial design, patient characteristics, and results, comparing outcomes with...

Five-year outcomes from the Evolut low risk TAVR bicuspid study

EuroPCR 2025: RESIL-Card achieves a major milestone - The resilience tool is ready for pilot testing!

20 May 2025

Launched in December 2023 by our community through the ‘We CARE Alliance’ and co-funded by the EU4Health work programme, the mission of the RESIL-Card project is to ensure that essential healthcare services for people with cardiovascular (CV) diseases are maintained during crises. Specifically, the project aims to...

RESIL-Card achieves a major milestone - The resilience tool is ready for pilot testing!

SMT’s Supraflex Cruz shows consistent and robust clinical outcomes across key global studies presented at TCT 2025

29 Oct 2025

Jupiter Endovascular announces positive results from SPIRARE I first-in-human study presented at TCT 2025

26 Oct 2025

Meril Life Sciences presents one-year outcomes from the LANDMARK randomized controlled trial at PCR London Valves 2025

16 Nov 2025

Indirect Industry Supported Grants for #PCRLV

A limited number of grants covering onsite registration and accommodation are available for healthcare practitioners who meet our Industry Partners’ selection criteria, check your eligibility and apply by 12 September!

Useful links in Interventional Cardiology

12 Oct 2016

We would like to share useful information and links to resources with you on Interventional Cardiology, medical professional societies, specialised websites and scoring tools.

Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies

22 May 2025 – From EuroPCR 2025

Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...

Meta-Analysis from the PROTECTED TAVR and BHF PROTECT-TAVI studies

EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years

21 May 2025

Didn’t find what you were looking for?